Compare Abeona Therapeutics Inc (ABEO) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VICI Properties Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while VICI Properties Inc trades at $26.31 (market cap $29.48B). The key difference: VICI Properties Inc is far larger — about 79× Abeona Therapeutics Inc's market cap, and VICI Properties Inc pays a 6.72% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VICI | |
|---|---|---|
Market Cap | $373.32M | $29.48B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $33.93 |
52-Week Low | $4.17 | $26.09 |
Enterprise Value | $228.22M | $46.70B |
Dividend Yield | — | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VICI Properties trades at $26.70, down 1.78% on the day, reflecting a bearish technical trend. The stock shows strong fundamentals with a P/E of 9.14, a net income margin of 76.83%, and consistent earnings beats in recent quarters. Recent news highlights its investment-grade balance sheet and a 6.8% dividend yield, though technical indicators signal caution with a bearish moving average consensus.
The outlook for VICI is positive based on fundamentals, with a consensus price target of $30.67 implying 15% upside. Risks include tenant concentration and market volatility, but the company's stable cash flows and analyst buy ratings (76.9%) support a favorable long-term view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
